Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Revance Therapeutics, Inc. (RVNC)

NEW YORK, December 15, 2021 (GLOBE NEWSWIRE) – Gainey McKenna & Egleston announce that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC) in the United States States District Court for the Northern District of California on behalf of investors who purchased or acquired Revance common stock between November 25, 2019 and October 11, 2021, inclusive (the “Class Period”).

According to the lawsuit, Defendants made false and / or misleading statements and / or failed to disclose that: (1) there were quality control deficiencies at the Company’s manufacturing facility for Daxibotulinum Toxin A For Injection (“DAXI”), the Company’s lead drug candidates; (2) the foregoing deficiencies reduced the likelihood that the US Food and Drug Administration (“FDA”) will approve the DAXI Biologics License Application (“BLA”) in its current form; (3) accordingly, the DAXI BLA was unlikely to receive FDA approval within the timeframe that the Company presented to investors; and (4) as a result, the Company’s public statements at all relevant times have been materially false and misleading. When the real details hit the market, the lawsuit claims that investors have suffered damage.

Investors who have purchased or otherwise acquired Revance Shares during the Class Action Period should contact the Company before February 8, 2022 The lead plaintiff’s application deadline. A lead plaintiff is a representative party who acts on behalf of other members of the group in directing the dispute. If you would like to discuss your rights or interests in relation to this class action lawsuit, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. from Gainey McKenna & Egleston at (212) 983-1300 or by email at or

Please visit our website at for more information on the firm.

Comments are closed.